Antivascular and Apoptotic Effects of Imatinib in GIST


J. C. Trent, H. Choi, D. Davis, K. Hunt, H. Macapinlac, D. McConkey, C. Charnsangravej, J. Abbruzzese, and Robert S. Benjamin

The University of Texas, M. D. Anderson Cancer Center Houston, TX USA



Connective Tissue Oncology Society

Background (cont)




Hypotheses

- Effects of imatinib begin during the first week of therapy
- Imatinib therapy perturbs vascular physiology in GIST
- Imatinib induces apoptosis of GIST cells

MDACC ID03-0023

Preoperative plus postoperative imatinib for patients with Kit(+) GIST




Patient Characteristics

Characteristic	Value
Age (median)	52 (range 38-67)
Gender (M/F)	7/6
Primary Site of Tumor	
- Stomach	6
- Small Intestine	5
- Colon	2

Preoperative Imatinib Toxicity Grade 3/4

Toxicity	Number of Patients		
	(<i>n</i> =13)		
Nausea/emesis	2		
Abdominal pain	1		
GI Hemorrhage	1		
Hypovolemia	1		
None	11		

PET Response at Day 5



Pre-imatinib

Post-imatinib (Day 5)

PET Response Data n=12

	3 Days	5 Days	7 Days	Total
Responders	3	2	3	8
Non-responder	1	2	1	4

Surgical Findings



Preoperative Imatinib (3 days)


No Preoperative Imatinib

Courtesy Kelly Hunt, M. D.

Perfusion Computed Tomography (CT)

- Allows quantitative measurement of tumor vascular physiology
- Non-invasive, rapid
- Validated in oncology
 - Detection of metastases
 - Indicator of malignancy
 - Assessment of response to therapy


Effect of Imatinib on Perfusion CT 5 days of therapy



Pre-imatinib

Post-imatinib (Day 5)

Effect of Imatinib on Perfusion CT



Effect of Imatinib on Vascular Physiology by Perfusion CT


Perfusion Parameter	Pre-Imatinib	Post-Imatinib	<i>P</i> Value
BF (mL/100g/min)	36.84	24.55	0.017
BV (mL)	3.90	2.84	0.005
MTT (s)	9.47	9.96	0.26


Laser Scanning Cytometry (LSC)

Immunofluorescent Staining of Target Antigen

Scan Specimen using the LSC to Generate a Tissue Map

Quantitate Cell Number Based on Gating Labelled cells Reported as a % of Total Cells Counted CD31 & TUNEL






Scattergram

Courtesy Darren Davis, Ph. D.

Effect of Imatinb on MVD 3 days of therapy


Pre-Imatinib

Post-Imatinib



CD-31 immunofluourescent staining of GIST vessels

Effects of Imatinib on MVD




MVD (%)


Endothelial Cell Apoptosis 3 days post-imatinib


CD31


TUNEL

Overlay









Vascular Effects of Imatinib


- GISTs with response by PET show a significant decrease in BF and BV after imatinib therapy
- There is a trend toward a decrease in MVD after imatinib
- Endothelial cell apoptosis was observed

Apoptotic Effects of Imatinib in GIST





5 days post-imatinib






Apoptosis After Imatinib






5 days post-imatinib

Effect of Imatinib on Apoptosis





Pre-Imatinib

Post-Imatinib

Immunofluourescent TUNEL Assay

Effect of Imatinib on Apoptosis

- Apoptosis was observed in GIST tissue after imatinib therapy by light microscopy and immunofluourescent LSC
- This effect is observe after less than 1 week of therapy

Conclusions

- Perfusion CT of GIST enables assessment of changes in vascular physiology early in imatinib therapy
- Immunofluourescent LSC allows detection of GIST cell and endothelial cell apoptosis after less than 1 week of therapy imatinib

Thanks

- Haesun Choi, Darren Davis, Kelly Hunt
- Bob Benjamin, Shreyas Patel, Lei Chen, Andy Burgess
- Raph Pollock, Peter Pisters, Janice Cormier, Barry Feig
- Arthur Charns, Homer Macapinlac
- Alex Lazar
- Jim Abbruzzese, David McConkey
- Beth Degracia, Caroline Oyedeji
- NIH K23 5-CA109060-01, NIH U54, Novartis Pharmaceuticals, MDACC PSTP